# Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

> **NCT00079378** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 84 (actual)

## Conditions studied

- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Adult Acute Myeloid Leukemia With Del(5q)
- Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Recurrent Adult Acute Myeloid Leukemia
- Recurrent Small Lymphocytic Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Untreated Adult Acute Myeloid Leukemia

## Interventions

- **DRUG:** decitabine
- **DRUG:** valproic acid
- **OTHER:** pharmacological study
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00079378
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2011-05
- **Final completion:** —
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2013-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00079378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00079378, "Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00079378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*